178 related articles for article (PubMed ID: 28155045)
1. Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib.
Necchi A; Pintarelli G; Raggi D; Giannatempo P; Colombo F
Invest New Drugs; 2017 Aug; 35(4):524-528. PubMed ID: 28155045
[TBL] [Abstract][Full Text] [Related]
2. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
[TBL] [Abstract][Full Text] [Related]
3. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.
Necchi A; Lo Vullo S; Mariani L; Raggi D; Giannatempo P; Calareso G; Togliardi E; Crippa F; Di Genova N; Perrone F; Colecchia M; Paolini B; Pelosi G; Nicolai N; Procopio G; Salvioni R; De Braud FG
Invest New Drugs; 2016 Apr; 34(2):236-42. PubMed ID: 26873642
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson MA; Mahoney MR; Tap WD; D'Angelo SP; Keohan ML; Van Tine BA; Agulnik M; Horvath LE; Nair JS; Schwartz GK
Ann Oncol; 2016 Oct; 27(10):1855-60. PubMed ID: 27502708
[TBL] [Abstract][Full Text] [Related]
5. Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.
Tayyar Y; Jubair L; Fallaha S; McMillan NAJ
Crit Rev Oncol Hematol; 2017 Nov; 119():59-65. PubMed ID: 29065986
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
O'Connor OA; Özcan M; Jacobsen ED; Roncero JM; Trotman J; Demeter J; Masszi T; Pereira J; Ramchandren R; Beaven A; Caballero D; Horwitz SM; Lennard A; Turgut M; Hamerschlak N; d'Amore FA; Foss F; Kim WS; Leonard JP; Zinzani PL; Chiattone CS; Hsi ED; Trümper L; Liu H; Sheldon-Waniga E; Ullmann CD; Venkatakrishnan K; Leonard EJ; Shustov AR;
J Clin Oncol; 2019 Mar; 37(8):613-623. PubMed ID: 30707661
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
[TBL] [Abstract][Full Text] [Related]
8. Association of the AURKA and AURKC gene polymorphisms with an increased risk of gastric cancer.
Mesic A; Rogar M; Hudler P; Juvan R; Komel R
IUBMB Life; 2016 Aug; 68(8):634-44. PubMed ID: 27270838
[TBL] [Abstract][Full Text] [Related]
9. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
Kurokawa C; Geekiyanage H; Allen C; Iankov I; Schroeder M; Carlson B; Bakken K; Sarkaria J; Ecsedy JA; D'Assoro A; Friday B; Galanis E
J Neurooncol; 2017 Jan; 131(1):41-48. PubMed ID: 27816996
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ
Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.
Melichar B; Adenis A; Lockhart AC; Bennouna J; Dees EC; Kayaleh O; Obermannova R; DeMichele A; Zatloukal P; Zhang B; Ullmann CD; Schusterbauer C
Lancet Oncol; 2015 Apr; 16(4):395-405. PubMed ID: 25728526
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB
Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990
[TBL] [Abstract][Full Text] [Related]
15. Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.
Zhou X; Nemunaitis J; Pant S; Bauer TM; Patel M; Sarantopoulos J; Craig Lockhart A; Goodman D; Huebner D; Mould DR; Venkatakrishnan K
Invest New Drugs; 2018 Apr; 36(2):240-247. PubMed ID: 28819760
[TBL] [Abstract][Full Text] [Related]
16. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
17. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Risk Associated with Genotype Polymorphisms of the Aurora Kinase a Gene (AURKA): a Case-Control Study in a High Altitude Ecuadorian Mestizo Population.
López-Cortés A; Cabrera-Andrade A; Oña-Cisneros F; Echeverría C; Rosales F; Ortiz M; Tejera E; Paz-Y-Miño C
Pathol Oncol Res; 2018 Jul; 24(3):457-465. PubMed ID: 28647900
[TBL] [Abstract][Full Text] [Related]
19. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.
Durlacher CT; Li ZL; Chen XW; He ZX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):585-601. PubMed ID: 26999067
[TBL] [Abstract][Full Text] [Related]
20. Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.
Qi L; Zhang Y
Tumour Biol; 2015 Mar; 36(3):1797-802. PubMed ID: 25366143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
